Aggressive Central Giant Cell Granuloma of the Maxilla: A Case Report
- Central giant cell granuloma (CGCG) is a benign but potentially aggressive osteolytic lesion that affects the jaws.
- The World Health Organization defines CGCG as a localized benign proliferation consisting of fibrous tissue with hemorrhage and haemosiderin deposits.
- CGCG occurs most commonly in the mandible, though it can also manifest in the maxilla.
Central giant cell granuloma (CGCG) is a benign but potentially aggressive osteolytic lesion that affects the jaws. While these lesions are non-neoplastic, they can cause significant destruction of the jawbone and extensive expansion of the facial structure, as seen in cases involving the maxilla.
The World Health Organization defines CGCG as a localized benign proliferation consisting of fibrous tissue with hemorrhage and haemosiderin deposits. This condition is characterized by the presence of osteoclast-like giant cells and reactive bone formation.
Characteristics and Clinical Presentation
CGCG occurs most commonly in the mandible, though it can also manifest in the maxilla. The etiology of the lesion remains uncertain, and It’s often described as an inflammatory proliferation, although it can behave similarly to an aggressive neoplastic process.
Medical literature distinguishes between aggressive and non-aggressive forms of the lesion. Approximately 30% of cases are classified as aggressive. These cases are typically characterized by:
- Rapid growth of the lesion.
- A size exceeding 5 centimeters.
- The presence of pain.
- Cortical perforation.
- Invasion of peripheral tissue.
- Root resorption of the teeth.
In the maxilla, these lesions can lead to extensive hemimaxillary expansion, which significantly alters the facial structure and requires specialized surgical intervention.
Diagnosis and Associated Conditions
CGCG represents approximately 10% of all benign tumors of the jaws. These lesions are most frequently found in the anterior region of the jaw.
Clinical research indicates that the presence of multiple lesions may be related to specific medical syndromes, including:
- LEOPARD syndrome.
- Noonan syndrome.
- Neurofibromatosis type 1.
Diagnosis is typically confirmed through histopathological examination, identifying the characteristic osteoclast-like giant cells within a vascular stroma.
Treatment Approaches
The primary treatment for central giant cell granuloma is surgical, often involving surgical excision, enucleation, or curettage. However, the approach may vary depending on the aggressiveness of the lesion.
In some cases, auxiliary therapies are used alongside surgery to reduce the trauma and morbidity associated with radical procedures. One such method is the use of intralesional corticosteroid infiltration, such as triamcinolone, following the Jacoway protocol.
The use of corticosteroids can help reduce the size of the lesion before surgical intervention. For example, one reported case of an aggressive CGCG in a 35-year-old female saw the total size of the lesion reduced by approximately 30% through triamcinolone infiltration before subsequent enucleation and curettage.
This combined approach allows for less radical surgery and can help prevent recurrence. In the aforementioned case, a one-year follow-up indicated no recurrence of the lesion following the combined corticosteroid and surgical treatment.